Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Publication | Open Access

DOI Full Paper Access

377

Citations

References

2020

Year

Michèle Cavo, Francesca Gay, Meral Beksaç, Lucia Pantani, Maria Teresa Petrucci, Meletios Α. Dimopoulos, Luca Dozza, Bronno van der Holt, Sonja Zweegman, Stefania Oliva,

The Lancet Haematology

Hematological MalignancyTransplantationMarrow TransplantationMedicineStem Cell TransplantationImmunologyHematologyMultiple MyelomaLenalidomide MaintenanceOncologyCell TransplantationBortezomib–lenalidomide–dexamethasone Consolidation Therapy